649 related articles for article (PubMed ID: 31732444)
41. Pharmacology and safety of tofacitinib in ulcerative colitis.
López-Sanromán A; Esplugues JV; Domènech E
Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
[TBL] [Abstract][Full Text] [Related]
42. Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
Vieujean S; Laharie D; Buisson A; Roblin X; Fumery M; Nancey S; Wils P; Altwegg R; Seidel L; Caron B; Peyrin-Biroulet L
Dig Liver Dis; 2024 Apr; 56(4):613-621. PubMed ID: 38065698
[TBL] [Abstract][Full Text] [Related]
43. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
Curtis JR; Regueiro M; Yun H; Su C; DiBonaventura M; Lawendy N; Nduaka CI; Koram N; Cappelleri JC; Chan G; Modesto I; Lichtenstein GR
Inflamm Bowel Dis; 2021 Aug; 27(9):1394-1408. PubMed ID: 33324993
[TBL] [Abstract][Full Text] [Related]
44. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.
Constant BD; Baldassano R; Kirsch J; Mitchel EB; Stein R; Albenberg L
J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):724-730. PubMed ID: 36122389
[TBL] [Abstract][Full Text] [Related]
45. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
Taxonera C; Olivares D; López-García ON; Alba C
Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
[TBL] [Abstract][Full Text] [Related]
49. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
[TBL] [Abstract][Full Text] [Related]
50. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
51. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
Nishio M; Ishii Y; Hashimoto Y; Otake H; Ogashiwa T; Tsuda S; Yasuhara H; Saigusa Y; Kimura H; Maeda S; Kunisaki R
Scand J Gastroenterol; 2018; 53(10-11):1236-1244. PubMed ID: 30353757
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
Verstockt B; Volk V; Jaeckel C; Alsoud D; Sabino J; Nikolaus S; Outtier A; Krönke N; Feuerhake F; De Hertogh G; Rosenstiel P; Vermeire S; Schreiber S; Ferrante M; Aden K
Aliment Pharmacol Ther; 2022 Jul; 56(2):282-291. PubMed ID: 35484689
[TBL] [Abstract][Full Text] [Related]
53. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
[TBL] [Abstract][Full Text] [Related]
54. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis.
Yu A; Ha NB; Shi B; Cheng YW; Mahadevan U; Beck KR
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3115-3124.e3. PubMed ID: 37187323
[TBL] [Abstract][Full Text] [Related]
55. Is tofacitinib a game-changing drug for ulcerative colitis?
Magro F; Estevinho MM
United European Gastroenterol J; 2020 Aug; 8(7):755-763. PubMed ID: 32552501
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran.
Jameshorani M; Vahedi H; Sadeghi A; Sima AR; Anushiravani A; Nateghi Beige H; Malekzadeh MM; Naserinejad S; Alatab S
Arch Iran Med; 2021 May; 24(5):354-363. PubMed ID: 34196200
[TBL] [Abstract][Full Text] [Related]
57. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
58. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
59. Tofacitinib for a Child with Refractory Steroid-Dependent Ulcerative Colitis: A Case Report and Review of the Literature.
Alajmi R; Alabdulhadi M; Alali AA; Shehab M
Am J Case Rep; 2021 Nov; 22():e934460. PubMed ID: 34767543
[TBL] [Abstract][Full Text] [Related]
60. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
